Vascular complications in hypertension: The VHAS study

Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values ≥160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP ≥115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes. Patients were randomly allocated to drug therapy for 2 years with either slow-release verapamil 240 mg once daily or chlorthalidone 25 mg once daily, with nonresponders receiving additional captopril 25 mg daily. A random group of eligible patients (n=494) was followed for a more extended period (4 years) using beta-mode ultrasound. The end point is the development of atherosclerosis detected by ultrasound imaging. The most interesting observation thus far is that in this population of middle-aged hypertensives without a history of previous cardiovascular events, about two thirds had asymptomatic carotid alterations. The study is ongoing.

Original languageEnglish
Pages (from-to)529-531
Number of pages3
JournalCardiovascular Drugs and Therapy
Volume9
Issue number3 Supplement
DOIs
Publication statusPublished - Aug 1995

Fingerprint

Verapamil
Blood Vessels
Atherosclerosis
Hypertension
Chlorthalidone
Captopril
Ultrasonography
Diabetes Mellitus
Myocardial Infarction
Research Personnel
Observation
Blood Pressure
Drug Therapy
Population

Keywords

  • atherosclerosis
  • captopril
  • chlorthalidone
  • essential hypertension
  • ultrasound imaging
  • verapamil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Vascular complications in hypertension : The VHAS study. / Zanchetti, Alberto.

In: Cardiovascular Drugs and Therapy, Vol. 9, No. 3 Supplement, 08.1995, p. 529-531.

Research output: Contribution to journalArticle

Zanchetti, Alberto. / Vascular complications in hypertension : The VHAS study. In: Cardiovascular Drugs and Therapy. 1995 ; Vol. 9, No. 3 Supplement. pp. 529-531.
@article{88bcc753161b4c8e9b2b46666515f9dc,
title = "Vascular complications in hypertension: The VHAS study",
abstract = "The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values ≥160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP ≥115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes. Patients were randomly allocated to drug therapy for 2 years with either slow-release verapamil 240 mg once daily or chlorthalidone 25 mg once daily, with nonresponders receiving additional captopril 25 mg daily. A random group of eligible patients (n=494) was followed for a more extended period (4 years) using beta-mode ultrasound. The end point is the development of atherosclerosis detected by ultrasound imaging. The most interesting observation thus far is that in this population of middle-aged hypertensives without a history of previous cardiovascular events, about two thirds had asymptomatic carotid alterations. The study is ongoing.",
keywords = "atherosclerosis, captopril, chlorthalidone, essential hypertension, ultrasound imaging, verapamil",
author = "Alberto Zanchetti",
year = "1995",
month = "8",
doi = "10.1007/BF00877865",
language = "English",
volume = "9",
pages = "529--531",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3 Supplement",

}

TY - JOUR

T1 - Vascular complications in hypertension

T2 - The VHAS study

AU - Zanchetti, Alberto

PY - 1995/8

Y1 - 1995/8

N2 - The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values ≥160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP ≥115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes. Patients were randomly allocated to drug therapy for 2 years with either slow-release verapamil 240 mg once daily or chlorthalidone 25 mg once daily, with nonresponders receiving additional captopril 25 mg daily. A random group of eligible patients (n=494) was followed for a more extended period (4 years) using beta-mode ultrasound. The end point is the development of atherosclerosis detected by ultrasound imaging. The most interesting observation thus far is that in this population of middle-aged hypertensives without a history of previous cardiovascular events, about two thirds had asymptomatic carotid alterations. The study is ongoing.

AB - The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values ≥160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP ≥115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes. Patients were randomly allocated to drug therapy for 2 years with either slow-release verapamil 240 mg once daily or chlorthalidone 25 mg once daily, with nonresponders receiving additional captopril 25 mg daily. A random group of eligible patients (n=494) was followed for a more extended period (4 years) using beta-mode ultrasound. The end point is the development of atherosclerosis detected by ultrasound imaging. The most interesting observation thus far is that in this population of middle-aged hypertensives without a history of previous cardiovascular events, about two thirds had asymptomatic carotid alterations. The study is ongoing.

KW - atherosclerosis

KW - captopril

KW - chlorthalidone

KW - essential hypertension

KW - ultrasound imaging

KW - verapamil

UR - http://www.scopus.com/inward/record.url?scp=0029068557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029068557&partnerID=8YFLogxK

U2 - 10.1007/BF00877865

DO - 10.1007/BF00877865

M3 - Article

C2 - 8562470

AN - SCOPUS:0029068557

VL - 9

SP - 529

EP - 531

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3 Supplement

ER -